Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma

Anti-Cancer Drugs

Volumn 19, Issue 5, 2008, Pages 465-475

  Saigal, Babita ^a   Glisson, Bonnie S ^a   Johnson, Faye M ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Docetaxel; Epidermal growth factor receptor; Erlotinib; Head and neck cancer; Treatment sequence

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LOW DRUG DOSE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STAINING; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS;

EID: 42349087644     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282fc46c4     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579-3584.
3. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164-2170.
4. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24:2666-2672.
5. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, et al. Somatic mutations of egfr gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11:2879-2882.
6. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, et al. Low incidence of mutations in EGFR kinase domain in caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006; 42:109-111.
7. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003; 25:67-73.
8. Myers JN, Holsinger FC, Bekele BN, Li E, Jasser SA, Killion JJ, et al. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch Otolaryngol Head Neck Surg 2002; 128:875-879.
9. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, et al. Epidermal growth factor receptor-targeted therapy with c225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7:1204-1213.
10. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase ii study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85.
11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
12. Forastiere AA, Shank D, Neuberg D, Taylor SGT, DeConti RC, Adams G. Final report of a phase ii evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (pa390). Cancer 1998; 82:2270-2274.
13. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14:1672-1678.
14. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005; 17:218-224.
15. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, et al. Zd1839 (Iressa), an egfr-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant mcf-7 adr human breast cancer cells. Int J Cancer 2002; 98:463-469.
16. Choe MS, Chen Z, Klass CM, Zhang X, Shin DM. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13:3015-3023.
17. Akita RW, Sliwkowski MX. Preclinical studies with erlotinib (tarceva). Semin Oncol 2003; 30:15-24.
18. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody imclone c225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8:1253-1264.
19. Hitt R, Irigoyen A, Nuñez J, Grau J, Garcia Saenz J, Pastor M, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). J Clin Oncol, 2007 ASCO Annu Meeting Proce 2007; 25:6012.
20. Wanebo HJ, Ghebremichael M, Burtness B, Spencer S, Ridge J, Forastiere A, et al. Phase II evaluation of cetuximab (c225) combined with induction paclitaxel and carboplatin followed by c225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ecog, e2303). J Clin Oncol, 2007 ASCO Annu Meeting Proc 2007; 25:6015.
21. Kim ES, Kies MS, Glisson BS, Tsao A, Ginsberg LE, Holsinger FC, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J Clin Oncol, 2007 ASCO Annu Meeting Proc 2007; 25:6013.
22. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 2007; 25:2178-2183.
23. Vermorken J, Mesia R, Vega V, Remenar E, Hitt R, Kawecki A, et al. Cetuximab extends survival of patients with recurrent or metastatic scchn when added to first line platinum based therapy - results of a randomized phase III (extreme) study. Am Assoc Cancer Research 2007; 48:6091.
24. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of zd1839 (iressa), an inhibitor of egfr tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
25. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-intact 2. J Clin Oncol 2004; 22:785-794.
26. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. Tribute: a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
27. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-intact 1. J Clin Oncol 2004; 22:777-784.
28. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 7:385-388.
29. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997; 89:341-343.
30. Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst 1997; 89:365-373.
31. Piperdi B, Ling YH, Perez-Soler R. Schedule-dependent interaction between the proteosome inhibitor bortezomib and the egfr-tk inhibitor erlotinib in human non-small cell lung cancer cell lines. J Thorac Oncol 2007; 2:715-721.
32. Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, et al. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 2001; 93:172-178.
33. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by zd-1839 (iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
34. Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003; 9:3183-3189.
35. Hernandez-Vargas H, Palacios J, Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 2007; 26:2902-2913.
36. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005; 4:1495-1504.
37. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11:6924-6932.
38. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
39. Chou TC, Rideout DC. The median-effect principle and the combination index for quantitation of synergism and antagonism, Synergism and antagonism in chemotherapy. San Diego, CA: Academic Press; 1991. pp. 61-102.
40. Chou TC, Riedeout D, Chou J, Bertino JR, Dulbecco R. Chemotherapeutic synergism, potential and antagonism. Vol. 2. Encyclopedia of human biology. San Diego, CA: Academic Press; 1991. pp. 371-379.
41. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of osi-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
42. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36:99-114.
43. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and powerblot. Clin Cancer Res 2002; 8:3910-3921.
44. Hanauske AR, Depenbrock H, Shirvani D, Rastetter J. Effects of the microtubule-disturbing agents docetaxel (taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Eur J Cancer 1994; 30A:1688-1694.
45. Gumerlock PH, Pryde BJ, Kimura T, Galvin IV, Scott SL, Mack PC, et al. Enhanced cytoxicity of docetaxel osi-774 combination in non-small cell lung carcinoma (NSCLC). Am Soc Clin Oncol Chicago, Illinois 2003; 22:2661.
46. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007; 13:3413-3422.
47. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an rb- and schedule-dependent manner. See: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001; 7:2155-2158, 2228-2236.
48. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006; 176:787-792.
49. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 2006; 5:1154-1165.
50. Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006; 12:6100-6105.
51. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995; 6:339-355, 363-368.
52. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, et al. A common signaling cascade may underlie 'Addiction' to the src, bcr-abl, and egf receptor oncogenes. Cancer Cell 2006; 10:425-435.
53. Solit DB, She Y, Lobo J, Kris MG, Scher HI, Rosen N, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005; 11:1983-1989.